Ketamine Therapy Blog — Mental Health Insights & Treatment Guides

Expert insights on ketamine therapy, depression, anxiety, PTSD, and mental health treatment — updated regularly by the Isha Health clinical team.

Ashwagandha Side Effects: What to Know Before You Start

Mar 24, 2026Mental Health

A clinical guide to ashwagandha side effects, drug interactions, contraindications, liver safety concerns, and how to choose a quality supplement.

Ashwagandha vs Antidepressants: Can a Supplement Replace SSRIs?

Mar 17, 2026Mental Health

Can ashwagandha replace antidepressants like SSRIs? We compare mechanisms, evidence strength, and risks, and explain why stopping prescribed medication for a.

TMS and Ketamine Together: What Clinicians Need to Know

Mar 15, 2026For Clinicians

Can patients do TMS and ketamine concurrently? A clinical guide based on the latest research for therapists navigating treatment decisions with their clients.

Is Ashwagandha Good for Anxiety? What the Evidence Says

Mar 10, 2026Mental Health

Does ashwagandha actually help with anxiety? We review the clinical evidence, including key studies on cortisol reduction and GABAergic activity, dosage.

Ketamine vs. Psilocybin for Neuroplasticity: How Psychedelics Reshape the Brain

Feb 27, 2026Research

A landmark Cell Reports study found that psychedelics including ketamine and psilocybin promote structural and functional neural plasticity.

Who Responds Best to Ketamine? What Research Says About Treatment Predictors

Feb 23, 2026Research

Research is identifying clinical predictors of ketamine response in treatment-resistant depression, including BMI, family history, and anxiety features.

Ketamine and the Gut-Brain Axis: Could Your Microbiome Influence Antidepressant Response?

Feb 17, 2026Research

Emerging research suggests ketamine may influence gut microbiome composition, and that the gut-brain axis could play a role in its antidepressant effects.

MDMA-Assisted Therapy for PTSD: What the Phase 3 Trial Showed

Feb 9, 2026Research

A Phase 3 trial published in Nature Medicine found that MDMA-assisted therapy produced significant improvements in severe PTSD.

Psilocybin for Depression: What the COMPASS Pathways Phase 2b Trial Found

Feb 2, 2026Research

The largest psilocybin trial for treatment-resistant depression, published in the New England Journal of Medicine, showed significant results at the 25mg dose.

Ketamine for Chronic Pain and Depression: Treating Two Conditions Through One Mechanism

Jan 27, 2026Research

Chronic pain and depression co-occur in up to 50% of patients. Learn how ketamine targets shared neural pathways to treat both conditions simultaneously.

Ketamine Long-Term Safety: What a Systematic Review of Side Effects Reveals

Jan 21, 2026Research

A Lancet Psychiatry systematic review examined ketamine side effects across clinical studies. What physicians and patients should know about long-term safety.

Ketamine and Sleep: How Slow Wave Changes May Signal Brain Healing in Depression

Jan 15, 2026Research

Research links ketamine's antidepressant effects to changes in slow wave sleep and BDNF, suggesting that sleep architecture improvements may reflect underlying.

Page 4 of 18